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Abstract In the past two decades, MRI has gained a major
role in research and clinical management of patients with
inflammatory arthritides, particularly in spondyloarthritis
(SpA), rheumatoid arthritis (RA), and osteoarthritis (OA).
MRI is regarded as the most sensitive imaging modality for
detecting early SpA in young patients with inflammatory
back pain and normal radiographs of the sacroiliac joints.
The recently published Assessment of SpondyloArthritis
International Society classification criteria for axial SpA
include for the first time a positive MRI demonstrating
sacroiliitis as an imaging criterion indicative of SpA
together with at least one clinical feature of SpA. Recent
data show that systematic assessment of sacroiliitis dis-
played on MRI has much greater diagnostic utility than
previously reported and highlight the diagnostic relevance
of structural lesions. In RA, MRI has predictive value for
the development of disease in new onset undifferentiated
arthritis, and MR pathology at disease onset is a highly
significant predictor of radiographic erosions. Consequently
MRI has been credited with an important role in the new
ACR/EULAR 2010 classification criteria for RA. In OA,
bone marrow edema (BME) and synovitis may serve as
biomarkers in interventional trials. Treatment interventions
targeting BME and synovitis observed on MRI in inflam-
matory arthritides may have a disease-modifying effect as
these lesions are potentially reversible and have been
shown to be associated with structural progression. Re-
search should focus on the prognostic significance of MRI
lesions in larger cohorts and whether adding MRI to routine
care improves clinical and radiographic outcome in patients
with inflammatory arthritides.
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Introduction
The introduction of magnetic resonance imaging (MRI) to
the field of medicine [1, 2], which lead to the Nobel Prize,
has revolutionized pathophysiologic concepts and clinical
decision making in many areas of clinical research and
daily practice. The past two decades have witnessed
advances in knowledge in inflammatory rheumatology
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disorders by adopting MRI both for research and routine
practice. These achievements may well represent just the
first step of ongoing progress in the evaluation of
inflammatory arthritides by MRI.
Several properties of MRI render this imaging modality
particularly attractive for assessing inflammatory arthriti-
des. The capability of visualizing both soft tissues and bone
by tomographic imaging with high spatial and contrast
resolution allows assessment of all structures involved in
the disease process. Moreover, its noninvasive technique
and its lack of ionizing radiation makes MRI an ideal
imaging tool for monitoring disease outcome and following
patients after treatment interventions. Current limitations
preventing a more widespread use of MRI are costs and
regionally limited availability. However, these expenses
have to be weighed against the treatment costs of expensive
biologic agents and the indirect costs incurred by delayed
diagnosis or by complications resulting from an undiag-
nosed inflammatory condition.
The goal of this article is to review the contributions of
MRI to research and clinical management in axial spondy-
loarthritis (SpA), rheumatoid arthritis (RA), and osteoar-
thritis (OA), which are the three most common
inflammatory conditions in rheumatology. A focus will be
on active lesions represented by bone marrow edema
(BME; also termed bone marrow lesion, BML) and
synovitis. These MRI signs of disease activity are poten-
tially modifiable by treatment. There is growing evidence
that these lesions are associated both with pain and with
structural progression in inflammatory arthritides, and
interventions targeting BME and synovitis may show a
disease-modifying effect. BME and synovitis may also
serve as biomarkers in interventional trials. At present,
histopathology data from areas of BME displayed by MRI
are limited. It is interesting that the uniform appearance of
BME in typical subchondral locations displayed by MRI in
inflammatory arthritides seems to reflect different histo-
pathological findings. In RA, where the quality of peri-
operative correlation studies between BME on MRI and
histopathology is highest, predominantly active cellular
infiltrates with a variety of cytokine signatures have been
found [3, 4]. Scarce data in SpA from vertebral facet joints
removed during spinal extension surgery and from biopsies
of the sacroiliac joint (SIJ) showed predominantly mono-
nuclear cell infiltrates with only partial correlation with
BME seen on preoperative MRI [5, 6]. In contrast, bone
specimens in OA obtained from patients with advanced
disease undergoing joint replacement surgery demonstrated
mainly nonspecific findings such as bone marrow fibrosis
or bone remodeling, whereas edema in the bone marrow
and cellular infiltrates were rare findings [7–10].
MRI has a key role in clinical research in SpA, RA, and
OA. Where the technique is available, MRI has also gained
an important position in daily routine for early diagnosis of
SpA. This is reflected by the inclusion of MRI as an
imaging criterion in the recently published Assessment of
SpondyloArthritis (ASAS) International Society classifica-
tion criteria for axial spondyloarthritis [11]. In RA, the
present data don’t yet justify a recommendation for routine
use of MRI in daily practice; however recent data have
confirmed the high predictive value of MRI for structural
progression, and the recent recommendations address the
use of imaging modalities in the American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) 2010 classification criteria for RA [12]. In
particular, the use of MRI is recommended in selected
patients in daily routine [13, 14]. MRI in OA is mainly
restricted to clinical research, although suspicion of a
differential diagnosis may require the occasional use of
MRI in routine care of patients [15].
MRI for axial spondyloarthritis
MRI in axial SpA—major component of new classification
criteria
The spectrum of SpA comprises the related disorders
ankylosing spondylitis (AS), psoriatic arthritis, enteropathic
SpA associated with Crohn’s disease and ulcerative colitis,
reactive arthritis, juvenile SpA, and undifferentiated SpA.
Imaging plays a major role in predominantly axial forms of
SpA, which are less accessible to clinical examination than
peripheral SpA. While sacroiliitis remains the hallmark for
the diagnosis of SpA, disability usually results from
inflammation of the spine with progressive axial ossification
[16].
Advances in the field of SpA over the past few years
include the application of MRI as a major diagnostic tool
and the introduction of antitumour necrosis factor alpha
(anti-TNFα) therapy [17]. Until recently, diagnosis after
clinical assessment relied primarily on radiographs demon-
strating sacroiliitis according to the modified New York
criteria [18]. While this approach continues to play a major
role in clinical practice, it has been shown that several years
may elapse before sacroiliitis becomes apparent on radio-
graphs [19], during which time patients may experience
significant symptoms and impairment of quality of life
comparable to those with established disease [20]. More-
over, patients with early SpA may respond to treatment
with anti-TNFα agents, which may be even more effective
than in those with established disease [21, 22]. MRI
abnormalities may precede radiographic changes by several
years [23].
The major relevance of MRI in recognition of early SpA
is reflected by the new axial SpA classification criteria
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developed by the ASAS [11]. For the first time, imaging is
included as a major criterion that may be either radiograph-
ic (as defined by the modified New York criteria [18]) or
MRI evidence of sacroiliitis, which allows classification of
patients with preradiographic disease. A companion expert
consensus statement by the ASAS/OMERACT working
group defined a positive MRI of the SIJ based solely on
active inflammatory lesions [24]. It requires subchondral or
periarticular BME on STIR sequence or osteitis on contrast-
enhanced T1-weighted (T1W) sequence highly suggestive
of sacroiliitis; BME needs to be present in at least two
lesions on a single SIJ slice or must be observed on two
consecutive slices if only one lesion is present.
Apart from the major role of MRI in recognition of
clinically suspected, yet radiographically unconfirmed early
SpA, MRI may be used to assess patients with established
SpA unresponsive to standard treatment or to evaluate
response to therapeutic interventions. Moreover, there is
growing evidence that inflammatory spinal lesions detected
by MRI may be predictive of new syndesmophyte
formation.
The spectrum of MRI lesions in sacroiliitis
Several groups have recently reported descriptions of active
and structural abnormalities in the SIJ that are usually based
on the combined information from both T1W and STIR
sequences. Active lesions include subchondral, ligamen-
tous, sacrotuberous, and capsular edema as well as
synovitis, capsulitis, joint space inflammation, and liga-
mentous enthesitis. Structural lesions include fat infiltra-
tion, erosion, bone sclerosis, and ankylosis. The
histopathology of bone marrow signal abnormalities in
SpA is poorly characterized. Histology findings of intersti-
tial, predominantly mononuclear cell infiltrates from CT-
guided biopsies of the SIJ [6] and bone tissue from
zygoapophyseal joints removed during spinal extension
surgery [5] showed a moderate correlation with bone
marrow inflammatory lesions on dynamic MRI or on STIR
sequences. Moreover, MRI detected only about half of the
inflammatory lesions evident on histopathology. Though
MRI can reveal diverse lesions, there have been only a few
attempts to achieve standardized and validated definitions.
Bone marrow edema Active lesions can be observed on
MRI within a few weeks of presentation of inflammatory
back pain [25, 26]. Subchondral edema can be reliably
detected on STIR sequences [27]. An online training
module for systematic assessment of edema in the SIJ has
been developed and validated by demonstrating increased
reliability of detection after review of the module [28].
Do contrast-enhanced MRI sequences improve the
detection of active SIJ lesions compared to STIR sequence
alone? It has been reported that a T1W fat-suppressed
sequence after administration of gadolinium contrast
(T1WGd) may enhance diagnostic utility for detection of
sacroiliitis as compared to the STIR sequence [29].
Although sensitivity for SpA was comparable at 65.7 and
62.9% for the STIR and T1WGd sequences, respectively,
24 and 13% were considered inconclusive, while disease
was ruled out in 34 and 47 patients by STIR and T1WGd,
respectively. Although the authors concluded that T1WGd
had superior diagnostic capacity, this was a retrospective
rather than a prospective inception cohort study, and the
indication for performing the MRI was left to the discretion
of the clinician. Because this may introduce significant
bias, further comparative study is necessary in early
inception SpA cohorts because contrast enhancement
doubles the time required for the patient to lie still in the
magnet as well as the costs of the procedure.
A study comparing STIR and gadolinium-enhanced
T1W sequences to detect active bone marrow lesions in
the SIJ of 40 SpA patients fulfilling the ESSG criteria (27
patients met the modified New York criteria) concluded that
both sequences performed nearly equally well [30]. A
previous report in 2005 did not show an advantage of
contrast-enhanced T1W sequence over STIR sequence
alone to detect spinal inflammation in 38 patients with AS
[31].
Erosion Bone erosion has been defined as full-thickness
loss of the dark appearance of either iliac or sacral cortical
bone of the SIJ with loss of the adjacent marrow signal on
T1SE images [32].
It has been suggested that so-called cartilage sequences,
such as T2W gradient echo or fat-saturated T1W (T1W
FS), may facilitate reliable detection of erosions. These
directly demonstrate cartilage as a thin zone of intermediate
to high signal intensity with an adjacent low signal intensity
cortex and a sharply defined bone margin. Erosions are
identified as high or intermediate signal defects in the
hypointense cortical bone on these sequences. One study
used both T1W and T1FS to identify erosions in the SIJ and
showed good reliability for an erosion score based on the
extent of involvement of the joint surface, although this
study did not directly compare these two sequences as
regards reliability of detection or diagnostic utility [32]. A
recent report compared T1W FS with spin-echo, three-
dimensional-fast low angle shot (3D-FLASH), and three-
dimensional-double excitation in the steady-state (3D-
DESS) sequences in a retrospective analysis of scans from
30 patients with suspected sacroiliitis and 9 healthy controls
[33]. These sequences provide higher resolution, greater
contrast, and lower partial volume effects in the assessment
of the cartilage. A similar number of patients demonstrated
bone and cartilage erosions for each of the sequences,
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although erosion scores for bone and cartilage based on
extent of involvement were significantly higher in 3D-
DESS and 3D-FLASH than T1W FS images. The superi-
ority of these sequences over T1W images in the reliable
detection of SIJ erosions and their contribution to diagnos-
tic utility requires further study.
Fat infiltration Fat infiltration is evident as bright signal on
T1W scans and is often seen in healthy individuals in the
SIJ. The fat infiltration observed in SpA patients often
occurs adjacent to subchondral bone, may have a distinct
border, and is seen in areas of ankylosis and adjacent to
other lesions such as edema and sclerosis. It likely indicates
prior inflammation though this has not been proven in
prospective studies. It is unknown which, if any, of these
characteristics contributes to diagnostic utility. A prelimi-
nary report from a controlled analysis of 64 individuals
concluded that fat infiltration in the SIJ per se has high
sensitivity but low specificity for SpA and that its
diagnostic utility primarily reflected the presence of
associated abnormalities, especially erosions [34].
Diagnostic utility of MRI in preradiographic sacroiliitis
The few studies that were reported over a decade ago
demonstrated that MRI had sensitivity and specificity in the
range of 54–95% and 83–100%, respectively, but most
studies employed gadolinium enhancement with dynamic
imaging and lacked age- and sex-matched controls [35–39].
This approach is not used in clinical practice because it is
costly, requires prolonged scanning times, and is unreliable.
The sum of this data has been incorporated into diagnostic
algorithms where the presence of a positive MRI has been
assigned a likelihood ratio (LR) of 9 for a diagnosis of SpA
[40].
The necessity for standardization of methodology as an
approach to knowledge transfer was elaborated in two
recent reports by the MORPHO International MRI Group,
which aimed at assessing diagnostic utility of MRI by
sequences commonly used in clinical practice. MRI scans
were assessed from patients with AS meeting modified
New York criteria as well as patients with preradiographic
SpA [41, 42]. In addition, scans were assessed from age-
and sex-matched controls that included healthy individuals
as well as those diagnosed with mechanical causes of back
pain. The methodological approach was unique in not only
implementing standardized definitions of active inflamma-
tory and structural lesions of the SIJ but also a customized
online data entry module based on a standardized approach
to recording abnormalities in the SIJ (available at www.
arthritisimaging.ca). The latter derived from the method
developed by the Spondyloarthritis Research Consortium of
Canada (SPARCC) for scoring inflammatory lesions in the
SIJ [43]. This is based on the division of each SIJ into
quadrants and then the assessment of active and structural
lesions on a dichotomous basis in all SIJ quadrants of each
semicoronal slice. This method has been standardized to
assess tilted coronal slices from anterior to posterior, and
such methodological details have been incorporated into an
online training module that has been validated for reliability
and sensitivity to change [44].
When readers were trained and calibrated to assess SIJ
scans and record lesions in this manner, much greater
diagnostic utility was evident than reported in earlier
studies. In patients without radiographic sacroiliitis, mean
sensitivity and specificity of MRI amongst five readers for
the clinical diagnosis of SpA made by a rheumatologist was
51 and 97%, respectively (positive LR=26.0, negative LR=
0.5). Diagnostic utility based solely on detection of BME as
defined in the ASAS proposal enhanced sensitivity to 67%
but reduced specificity to 88%. This was because a single
BME lesion in the SIJ was observed in up to 27% of
controls, and BME meeting the ASAS proposal for a
positive MRI was recorded concordantly in 23% of
mechanical back pain patients and 7% of healthy controls.
On the other hand, erosions were recorded concordantly in
only 4% of mechanical back pain patients and 2% of
healthy controls, and so the inclusion of erosions in
addition to BME further enhanced sensitivity to 81% but
without changing specificity. Erosions were detected in half
of the preradiographic SpA patients, which demonstrates
that structural damage of the SIJ starts early in the disease
course and contributes substantially to diagnostic utility
(Fig. 1).
In a second report from the MORPHO group [42], the
authors demonstrated that rheumatologists primarily base
diagnostic decisions on the finding of BME on the STIR
sequence, while experienced radiologists base decisions on
information available from both the T1W and STIR
sequences, emphasizing the importance of structural
lesions. Moreover, diagnostic utility is enhanced when
rheumatologist readers are trained to specifically recognize
abnormalities on T1W MRI. This is not surprising because
abnormalities may often be subtle on one sequence, and the
combined information from both sequences may enhance
confidence in diagnostic decision making. This observation
is also important in pointing to a major unmet need in the
continuing education of rheumatologists to achieve an
informed dialogue with the radiologist.
MRI for recognition of spinal inflammation
A set of definitions for active and structural lesions in the
central, lateral, and posterior compartment of the spine has
been reported by the Canada-Denmark MRI International
Working Group, and reference images depicting these
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lesions are available at www.arthritisdoctor.ca [45, 46].
Good to very good interobserver reliability was reported for
most of these lesion definitions [47, 48].
One study of WBMRI that included patients with
preradiographic SpA and age- and sex-matched controls
assessed the diagnostic utility of active spinal inflammatory
lesions and showed that the presence of two or more
vertebral corner BME lesions had optimal diagnostic utility
for SpA (sensitivity 69% and specificity 94%, respectively),
especially when located in the thoracic spine [49]. A single
vertebral corner BME lesion was observed in up to 26% of
healthy controls aged 45 years or less, which is a relevant
finding for routine practice to avoid misclassification of
healthy individuals as having SpA on the basis of an
isolated or doubtful corner inflammatory lesion, particularly
if seen in the vicinity of a degenerating disc. Another study
focused on the diagnostic utility of vertebral corner BME
lesions and of vertebral corner fat lesions separately and
concluded that a cut-off of three or more BME lesions and
of five or more fat lesions provided optimal diagnostic
utility [50, 51]. However, the heterogeneous control group
was not age- and sex-matched, the patients had long-
standing AS, the influence of spinal location of lesions on
diagnostic utility was not assessed and the study design was
retrospective. There is a need for more data from systematic
studies in a younger population with SpA and age- and sex-
matched controls before conclusions on the diagnostic
utility of structural spinal lesions can be drawn.
Routine scanning protocols of the spine may not include
the lateral segments of the thoracic spine where lesions may
be observed at sites such as the costo-vertebral and costo-
transverse joints. This is particularly relevant in the
presence of even a slight degree of scoliosis, which occurs
in about 70% of individuals. When scanning the spine of a
patient suspected as having SpA, the number of sagittal
slices should be increased to ensure that also the lateral
spinal segments are depicted. A systematic analysis in
patients with established AS showed that inflammatory
lesions were more frequent in lateral versus central seg-
ments in the thoracic spine [52]. In one study where the
diagnostic utility of active spinal lesions was assessed in
early SpA, the presence of active lesions in the lateral
segments had very high specificity for SpA but lacked
sensitivity [49]. Furthermore a recent study demonstrated
Fig. 1 MRI to confirm a diagnosis of preradiographic spondyloar-
thritis. A 27-year-old, HLA-B27-negative female patient with inflam-
matory back pain since 19 months. a Pelvic radiograph. The
radiographic modified New York criteria are not met. b MRI of the
sacroiliac joints, STIR sequence. Bone marrow edema shows in the
sacral portion of both sacroiliac joints and in the right distal ilium
(broken arrows). c MRI of the sacroiliac joints, T1SE sequence. A
small erosion is seen in the distal iliac part of the left sacroiliac joint
(solid arrow). d MRI of the sacroiliac joints 9 months later, T1SE
sequence. The erosive process in the distal iliac portion of the left
sacroiliac joint is demarcated more clearly (solid arrow). The right
iliac joint part shows decreased signal intensity with small bright areas
(arrowheads). This may represent bone sclerosis with areas of fat
infiltration or metaplastic tissue. The overlaying cortical bone seems
preserved
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inflammatory lesions also in the posterior spinal elements in
a majority of AS patients indicating that scrutiny of
posterior spinal structures is essential [53].
During the last few years, multichannel and multicoil
technology has been introduced into clinical MR scanners.
This whole body (WB) MRI method, which provides
comprehensive assessment of systemic disorders, allows
the scanning of the SIJ, the entire spine, the anterior chest
wall, and the shoulder and pelvic girdle within 30 min
without repositioning the patient. Scanning the entire spine
in one single examination is more convenient for the patient
and less time consuming than separate imaging of the upper
and lower halves of the spine by conventional MRI.
Imaging of the lower extremities is an additional option
that may be relevant for some patients with concomitant
peripheral enthesitis, but this has to be weighed against an
additional examination time of 20 min. WB MRI of the SIJ
and spine has been shown to correlate well and demonstrate
comparable reliability to conventional MRI for the detec-
tion of active inflammatory lesions in patients with
established AS [54, 55]. However, it depicts the SIJ in the
coronal plane rather than the tilted coronal plane used in
conventional MRI so that the images do not focus on the
cartilaginous portion of the joint. It therefore requires
further assessment of diagnostic utility compared to
conventional imaging in early SpA.
MRI to assess patients with established axial SpA
unresponsive to standard treatment or to monitor response
to therapy
Patients with established axial SpA may have both
inflammatory and mechanical sources of back pain, and it
may be difficult to distinguish between these on clinical
grounds. In this setting, MRI may be useful to confirm
active inflammatory features of SpA and as an objective
measure of disease activity before initiating long-term
treatment with expensive TNFα inhibitors. There is
evidence that widespread inflammation in the spine
displayed by MRI may be predictive of a favorable clinical
response to anti-TNFα treatment [56]. Response to treat-
ment with anti-TNFα agents may be even more pronounced
in very early disease that is detected only by MRI than in
patients with established radiographic disease [21, 22].
Several scoring systems to assess SIJ and spinal
inflammation have been developed for clinical research
to objectively monitor response to treatment. As an
example, the SPARCC indices were used to assess
disease activity in both the SIJ and spine in a recent
randomized controlled trial of adalimumab in active AS.
They were shown to be reliable and highly discrimina-
tory between treatment groups [27]. Persisting back pain
in AS patients despite anti-TNFα treatment may be due to
physical deconditioning after longstanding disease or
unrelated mechanical causes and not attributable to failure
of the biologic agent. An MRI documenting an improve-
ment in axial inflammation may influence decision
making towards physiotherapy rather than switching to
another anti-TNFα agent.
A combination of MR and high resolution CT with
multiplanar reconstruction showed the best sensitivity to
detect transspinal fractures in an ankylosed spine [57, 58]
(Fig. 2). These serious fractures through intervertebral
syndesmophytes, the former disc, and the posterior spinal
elements carry a substantial risk of spinal cord injury [59]
and are very difficult to locate by standard radiography in
most instances.
Emerging role of MRI to predict spinal ossification
Three recent studies concluded that inflammatory spinal
lesions detected by MRI are predictive of new syndes-
mophytes as shown on spinal radiographs 24 months
later, although the association with progression differed
among studies [60–62]. New syndesmophytes developed
significantly more frequently in vertebral corners with
inflammation than in those without inflammation seen on
baseline MRI. Interestingly, vertebral corner inflammation
that resolved upon treatment with anti-TNFα agents was
more strongly associated with new syndesmophyte forma-
tion [62]. However, vertebral corners that appeared normal
on MRI also developed new bone formation. Further
research in larger cohorts is needed to determine the
prognostic significance of spinal inflammation on MRI
and whether progression can be modified by treatment
with biologics, especially if therapy starts early in the
disease course.
MRI in daily routine for patients suspected
to have axial SpA
Patients presenting with clinical features of SpA with
equivocal radiographs should be further investigated using
T1W and STIR MRI of the SIJ scanned in the tilted coronal
orientation as the principal diagnostic tool, especially if they
are B27-positive [63]. There are presently no data supporting
the routine evaluation of the spine in addition to the SIJ in
the absence of symptoms in the spine and/or chest wall. In
that setting the radiologist should be alerted to the
requirement for an imaging protocol that ensures visualiza-
tion of lateral segments (available at www.arthritisdoctor.ca).
The finding of unequivocal BME and erosions in the SIJ
carries a high probability for SpA. In addition, the presence
of active spinal inflammatory lesions, especially in the
thoracic spine and in the lateral segments, substantially
increases the likelihood of SpA.
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MRI in rheumatoid arthritis
The spectrum of MRI lesions in RA and their
histopathologic correlation
MRI allows assessment of all the structures involved in RA,
i.e., synovial membrane, tendons and tendon sheaths, intra-
and extraarticular fluid collections, cartilage, bone, and
ligaments. MRI has been shown to be more sensitive than
clinical examination and radiographs for detection of
inflammatory and destructive joint changes in early RA
(Fig. 3). MRI and histopathological signs of synovial
inflammation are closely correlated [64–66]; in a study of
metacarpophalangeal (MCP) joints in patients with early
and with established RA, miniarthroscopy confirmed the
presence of bone pathology in all joints with MRI bone
erosions and histologic and macroscopic synovitis in all
joints with MRI synovitis [67]. MRI BME represents
inflammatory infiltrates in the bone marrow, i.e., osteitis,
as demonstrated by comparison with histological samples
obtained at surgery in RA patients [3, 4]. Whereas erosions
reflect bone damage that has already occurred, BME
appears to represent the link between joint inflammation
and bone destruction.
A high level of agreement for detection of bone erosions
in wrist and MCP joints in RA patients (concordance at 77–
90% of sites) between MRI and computed tomography
(CT), the gold standard reference for detection of bony
Fig. 2 Transspinal fracture in a patient with longstanding ankylosing
spondylitis and fusion of the thoracolumbar segment. A 57-year-old
male patient with HLA-B27-positive ankylosing spondylitis. The
thoracolumbar spine was completely ankylosed after a disease
duration of 32 years. The patient complained about increasing back
pain since 3 years without recalling an initiating event. The reason for
referring the patient was the question whether TNFα-inhibitor therapy
should be started due to persistent flare of ankylosing spondylitis. a
Conventional radiography of the thoracolumbar spine. Syndesmo-
phyte bridging of all lumbar levels (broken arrows). Advanced
degenerative bony changes on level Th 11 / Th 12 (solid arrow). b
Whole body MRI of the spine, STIR sequence. Active inflammation
with bone marrow edema in adjacent anterior vertebral corners Th 2
and Th 3 (broken arrow). Polymorph increased signal intensity on
level Th 11 / Th 12 (solid arrow). c CT of the thoracolumbar spine.
Old transspinal fracture through syndesmophytes, vertebral disc, and
posterior elements of the spine (solid arrows) with marked secondary
degenerative changes
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destruction, documents that MRI erosions represent true
bone damage [68–71].
The majority of MRI studies in RA investigated knee,
wrist, or finger joints. Reports on other peripheral joints are
few and not essentially different. Although only one formal
comparison with follow-up of other joints exists, MRI of
unilateral MCP and wrist joints are most commonly
recommended for MRI follow-up of RA patients, whereas
MRI of other joints is only to be obtained if specifically
clinically indicated.
Compared with radiography, MRI offers clear advan-
tages but also has disadvantages due to increased cost and
Fig. 3 MRI findings in patients with early rheumatoid arthritis. a–c
Coronal STIR sequence of the wrist and metacarpophalangeal joints of
three different patients with early rheumatoid arthritis. a shows no
bone marrow edema, b bone marrow edema (high signal intensity) in
many wrist bones, but not in the metacarpophalangeal joints, whereas
c shows bone marrow edema in various wrist bones as well as in the
second metacarpophalangeal joint (arrow). d Coronal T1SE sequence
and e axial T1SE sequence of the same patient as illustrated in c.
These images show bone erosion, confirmed in two planes, in the
second metacarpal head (arrow). Courtesy Susanne J. Pedersen, MD,
Copenhagen
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lower availability. However, MRI costs represent only a
fraction of the total expense incurred in the management of
RA patients when the costs of biological RA treatment or
the indirect costs of sick leave/early retirement are
considered. Dedicated extremity MRI units are increasingly
used and offer improved patient comfort at lower cost than
conventional MRI units [72–80]. The better of the
dedicated low-field MRI units provide similar information
on erosions and synovitis as conventional high-field MRI
devices [75, 76]. However, performance characteristics of
different machines differ widely [81], emphasizing the need
for careful testing of the individual machines.
Optimal MRI assessment of synovitis requires use of
intravenous gadolinium contrast media, while assessment of
BME and erosion does not [82]. Thus, for assessment of
synovitis, BME, and erosions, a pre- and post-contrast T1-
weighted sequence in two planes plus a T2-weighted fat-
saturated or short tau inversion recovery (STIR) sequence is
recommended [83] (Fig. 4).
Monitoring disease activity and structural damage
To be valuable for monitoring joint inflammation and
destruction, a measure must be reproducible and sensitive
to change [84]. MRI allows quantitative measurement of
the early contrast augmentation (“enhancement”) rate after
intravenous injection of gadolinium, which reflects the
degree of synovitis, the measurement of synovial volume,
as well as less detailed (qualitative: presence/absence;
semiquantitative: scoring) evaluation of synovitis and bone
erosions. In observational studies and randomized clinical
trials, semiquantitative scoring has been the most frequently
used approach. The OMERACT (Outcome Measures in
Rheumatology) RA MRI scoring system (RAMRIS)
involves semiquantitative assessment of synovitis, bone
erosions, and BME in RA finger and wrist joints [83]. This
method was developed and validated through iterative
multicenter studies under OMERACT and EULAR banners
[83, 85–88]. Consensus MRI definitions of important joint
pathologies and a “core set” of basic MRI sequences were
also suggested [83].
The OMERACT erosion scores are closely correlated
with erosion volumes estimated by MRI and CT [69, 70].
Using the RAMRIS, very good intrareader reliability, good
interreader reliability, and a high level of sensitivity to
change have been reported, demonstrating that the OMER-
ACT RAMRIS system, after proper training and calibration
of readers, is suitable for monitoring joint inflammation and
destruction in RA [89, 90]. A EULAR-OMERACT RA
MRI reference image atlas has been developed, providing
an easy-to-use tool for standardized RAMRIS scoring of
MR images for RA activity and damage by comparison
with reference images [91]. Scoring systems for tenosyno-
vitis [92] and joint space narrowing [93] may be used in
addition to the OMERACT scoring system.
The OMERACT synovitis score is sensitive to change
over weeks as well as months, and MRI, as assessed
according to the OMERACT system, is increasingly used in
trials of biologic agents [71, 94–100]. Haavardsholm et al.
reported that a combined score of synovitis, tenosynovitis,
and BME was more sensitive than conventional biomarkers
and clinical measures as well as the individual MRI
parameters [101].
Quantitative methods of synovitis (synovial membrane
volumes and post-contrast enhancement rates), which in
knee joints have been shown to be closely related with
histopathological synovitis [64–66] and to be sensitive to
change [65, 102], have only been used sparsely in clinical
trials, probably due to them being laborious (particularly
the measurement of synovial volume) and/or having limited
reproducibility with multicenter use (particularly early
enhancement rates by dynamic MRI). However, recent
software improvements, providing more automated methods,
potentially increase assessment speed and reproducibility
[103–107]. This encourages the reappraisal of the usefulness
of such quantitative methods.
Several studies have demonstrated that MRI is more
sensitive than radiography for monitoring erosive progres-
Fig. 4 MRI to detect (teno-)synovitis in a patient with early
rheumatoid arthritis. Axial T1SE sequence of the second to fifth
metacarpophalangeal joints in a patient with early rheumatoid arthritis
before (a) and after (b) intravenous contrast agent injection. Severe
synovitis is seen in all metacarpophalangeal joints (horizontal
arrows). Flexor tendon tenosynovitis is also noted, particularly at the
second and third finger (vertical arrows). Courtesy Susanne J.
Pedersen, MD, Copenhagen
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sion in individual joint regions [108–111]. RAMRIS
scoring of unilateral wrist and MCP joints is more sensitive
to change than Sharp/van der Heijde radiography scoring of
bilateral hands, wrist joints, and forefeet [112].
The superior sensitivity to change and discriminatory
ability of MRI compared to radiography has been demon-
strated in randomized controlled clinical trials (RCTs) [94,
113, 114]. Quinn et al. demonstrated a significantly lower
erosion progression rate by MRI, but not by the Sharp/van
der Heijde radiography method, in 12 early RA patients
treated with methotrexate plus infliximab compared to 12
patients receiving methotrexate alone [94]. This was the
first study to verify that the use of MRI in RCTs allows
shorter observation periods and/or fewer patients for
discriminating between different therapies concerning re-
duction of structural joint damage. This has been confirmed
by subsequent studies [113, 115]. A recent large study of
318 methotrexate-naïve patients demonstrated that inhibi-
tion of erosive progression by biological therapy compared
to placebo can be demonstrated by MRI using half the
patients and half the follow-up time of radiography [116].
These latter data reinforce the superior sensitivity of MRI as
compared to radiography assessment for measuring change
owing to erosive damage.
Diagnostic utility of MRI in undifferentiated
peripheral arthritis
A number of relatively small studies (≤50 patients per
study) provided ambiguous results regarding the differential
diagnostic value of MRI [117–121]. Recently, data from
two large follow-up studies of undifferentiated arthritis
have allowed a more thorough investigation of the utility of
MRI to diagnose RA [122, 123]. Tamai et al. investigated
129 patients with nonclassifiable arthritis despite routine
examination, including C-reactive protein and biochemical
tests, and developed a prediction model containing anti-
cyclic citrullinated peptide (anti-CCP) and/or IgM rheuma-
toid factors (RF), MRI-proven symmetric synovitis, and
MRI-proven BME and/or bone erosion. Of patients positive
for more than two of these variables, 71.3% developed RA
within 1 year (specificity 75.9% and sensitivity 68.0%,
respectively). Presence of BME had a positive predictive
value of 86.1% for subsequent development of RA [122].
In a study of 116 patients with early undifferentiated
arthritis, Duer-Jensen et al. documented that MRI BME in
metatarsophalangeal (MTP) and wrist joints is an indepen-
dent predictor of future RA in patients with early
undifferentiated arthritis. A prediction model, including
clinical hand arthritis, morning stiffness, positive RF, and
MRI BME score in MTP and wrist joints correctly
identified the development of RA or non-RA in 82% of
patients [123].
Two systematic literature reviews have been published
recently [124, 125], but too early to include the study by
Duer-Jensen et al. [123]. The former study states that
widespread use of MRI for diagnosing RA is scientifically
not justified, because the sensitivity and specificity of MRI
findings for RA differ substantially among studies, depend-
ing upon the criteria applied. However, the authors empha-
size that the diagnostic performance of MRI was better when
lower quality studies or studies in RA patients with longer
disease duration were excluded [124]. A systematic literature
review by Machado et al. concludes that BME and combined
synovitis and erosion pattern seem useful in predicting
development of RA from undifferentiated peripheral arthritis.
The difference in conclusions seems partly explained by
whether poor-quality studies are included [124] or not
included [125] in the systematic literature review.
A new role for MRI has recently been added. Due to the
limited sensitivity of the ACR 1987 classification criteria
for RA in early disease, new criteria have been developed
and recently reported, the ACR/EULAR 2010 criteria [12].
Classification as definite RA is based on the presence of
definite clinical synovitis (swelling at clinical examination)
in one or more joints, absence of an alternative diagnosis
that explains the synovitis, and achievement of a total score
≥6 (range 0–10) from the individual scores in four domains:
number/site of involved joints (range 0–5), serologic
abnormality (range 0–3), elevated acute-phase response
(range 0–1), and symptom duration (range 0–1) [12]. MRI
and ultrasound may be used to detect joint inflammation
and to count joints in the “joint involvement” domain of the
new RA classification criteria [13, 14].
In summary, two large studies document an independent
predictive value of MRI for the development of RA,
implying a diagnostic utility when used in combination
with clinical parameters. Furthermore, MRI and ultrasound
have an important role in the recent ACR/EULAR 2010
classification criteria for RA. Thus, MRI could be used in
routine clinical practice for confirming an early diagnosis of
RA made on clinical grounds.
Prognostication
Various studies have reported that MRI pathology (synovitis,
bone erosions or, most often, BME) of the wrist and MCP
joints at disease onset in early RA predicts radiographic
erosions [108, 126–134]. Some looked at the short-term
predictive value of MRI after 1 year [108, 126, 128, 130,
131], whereas other studies had 2 [128, 132], 3 [134], 5
[133], 6 [127], or 10 years [129] of follow-up. All studies
found MRI to be a highly significant predictor of radio-
graphic erosions.
With the exception of two early RA cohorts [131, 132],
all MRI studies in RA did not include anti-CCP or take into
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account other potential prognostic markers such as smoking
or shared epitope carriage. Haavardsholm et al. [131]
reported BME and male gender (but not anti-CCP) to be
independent predictors of radiographic progression after
1 year in a single-center cohort of 84 patients treated
according to standard clinical practice. A study by Hetland
et al. was the first clinical trial with a standardized
treatment protocol that investigated the predictive value of
a variety of potential prognostic markers including both
imaging modalities MRI and conventional radiography,
immunologic (anti-CCP, IgM RF, and IgA RF), environ-
mental (smoking, educational level), genetic (shared epi-
tope), and disease activity markers [132]. The main finding
was that in this comprehensive model, MRI BME at
presentation was the strongest independent predictor of
radiographic progression 2 years later in early RA patients
as determined in both multivariate linear and logistic
regression analyses. Three-year [135] and 5-year [133]
follow-up studies in the two respective cohorts have
documented that MRI BME is also a predictor of long-
term radiographic progression. A recent systematic litera-
ture review, not incorporating the latest data, reports that
when studies of all qualities are included in the analysis, the
sensitivity and specificity of MRI findings for predicting
erosive progression are so variable that the authors do not
recommend clinical use of MRI for this purpose. However,
they also note that BME was predictive of erosions if only
the highest quality data were included in the analysis [124].
A relation between baseline MRI findings and long-term
functional disability has only been documented in one
study [136]. Data from the same cohort revealed that
extensive MRI BME and erosions at the wrist in early
rheumatoid arthritis predicted tendon dysfunction and
impaired hand function [137]. Furthermore, a high baseline
MRI tendinopathy score was predictive of tendon rupture at
6 years (odds ratio 1.52) [138]. Further studies are required
to determine the clinical relevance of these findings.
Another issue of high clinical importance is whether
MRI is useful in patients in clinical remission to predict the
disease course. Residual synovitis on MRI is frequent in
patients in clinical remission [139, 140]. The impact of
subclinical imaging findings has been studied by Brown
and coworkers [141]. Seventeen controls and 102 RA
patients on conventional treatment judged to be in
remission by their treating rheumatologists underwent
clinical, laboratory, functional, and quality of life assess-
ments during a 12-month period. Radiographs of hands and
feet, and MRI and ultrasound of unilateral hand and wrist
were performed at baseline and after 12 months. Despite
clinical remission, 19% of patients experienced progression
in radiographic joint damage during the study period.
Baseline ultrasound synovial hypertrophy, ultrasound pow-
er Doppler signal and MRI synovitis scores in individual
joints were significantly associated with progressive radio-
graphic damage. The study encourages further exploration
of MRI and ultrasound for predicting the disease course and
for evaluating disease status, including defining what
constitutes true disease remission.
MRI in osteoarthritis
MRI has become the imaging modality of choice to assess
active and structural joint lesions in OA. The main focus of
interest for MRI in OA is clinical research whereas routine
use of MRI for the evaluation of patients with OA in daily
practice is not justified by currently available data [15]. In
clinical practice, MRI for OA may be ordered to exclude
relevant conditions in the differential diagnosis such as
avascular osteonecrosis or perhaps to assess the extent of
structural lesions prior to joint replacement surgery. An
emerging indication for daily routine is preradiographic OA
where early subtle joint pathology can be detected by MRI
long before structural changes are seen on radiography.
Research using MRI in OA has focused on the knee joint
because this large joint allows good discrimination of
anatomical structures, has a relatively thick articular
cartilage compared to other joints, and because the
prevalence of knee OA in the population is high [142].
Semiquantitative multi-feature whole-joint assessment
systems in knee OA
Whole joint MRI evaluation methods reflect the concept of
knee OA as a multifactorial disorder of the whole synovial
joint organ resulting in changes in structure and function.
MRI captures many features of soft tissue, cartilage, and
bone that are relevant to clinical manifestations, functional
impairment, or pathophysiology of OA. These articular
features include bone marrow lesions (BML), joint effu-
sion, synovitis, and bursitis that represent active lesions as
well as structural features such as articular cartilage
degeneration, subchondral bone attrition and cysts, osteo-
phytes, meniscal, cruciate and collateral ligament integrity,
and intraarticular loose bodies.
Several semiquantitative whole joint scoring systems
have been proposed: the Whole Organ Magnetic Resonance
Imaging Score (WORMS) [143], the Knee Osteoarthritis
Scoring System (KOSS) [144], the Boston-Leeds Osteoar-
thritis Knee Score (BLOKS) [145], and the system
proposed by Biswal and colleagues [146]. The scoring
modules apply different subregional divisions for the femur
and the tibial plateau. None of them uses contrast-enhanced
MRI. To date no single whole-joint scoring method has
gained widespread acceptance as a standard reference for
clinical research. A comparison between these scoring
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systems regarding construct validity is limited by the
absence of histopathological data while assessment of
discriminatory capacity is limited by the absence of
therapeutic modalities that have major treatment effects.
In a cross-sectional study of 115 knees with radiographic
OA at high risk of cartilage loss, the WORMS and BLOKS
scoring systems performed similarly for prevalence and
severity of cartilage loss, bone marrow lesions, and
meniscal damage [147]. A comparison of 1.0 Tesla
extremity MRI versus large-bore 1.5 Tesla MRI using the
WORMS system showed moderate (weighted kappa for
effusion and synovitis 0.53 and 0.54, respectively) to
substantial agreement (0.75 and 0.71 for cartilage and
BME, respectively) between the two techniques [148].
Quantitative measurement methods have also been
developed to assess cartilage integrity in knee OA. These
systems are less observer-dependent and may better detect
small changes in the cartilage structure over large areas
compared to semiquantitative methods. However, quantita-
tive measurement requires specialized software and time-
consuming segmentation between different articular struc-
tures by trained operators [142].
Bone marrow lesions and synovitis
MRI signs of disease activity such as BML and synovitis/
joint effusion are particularly interesting as they are
potentially modifiable by treatment [149]. Interventions
targeting BML and synovitis may not only result in
symptomatic improvement but may have a potential for
disease modification as active MRI lesions are associated
with both knee pain and progression of structural damage.
It is possible that osteochondral fracture and subsequent
osteonecrosis may develop in some cases as a consequence
of weakening of inflamed bone rather than the inflamma-
tion developing as a response to the injury or necrosis.
Bone marrow lesions BML appear on T2-weighted sequen-
ces as ill-defined areas of increased signal intensity (Figs. 5
and 6). The pathophysiology of BML is poorly understood.
Histology of BML in knee and hip joint tissue removed at
total joint replacement surgery in patients with advanced OA
showed predominantly nonspecific findings such as bone
marrow fibrosis and necrosis or trabecular microfractures,
but only sparse interstitial edema [7–10]. These histopathol-
Fig. 5 Discrepancy between se-
verity of hyaline cartilage
damage and presence of bone
marrow lesions. Bilateral knee
MRI (right knee a and b, left
knee c and d) with short tau
inversion recovery (STIR) and
proton density (PD) images. A
60-year-old woman with bilat-
eral knee pain and instability.
Right knee symptoms have been
present for longer, and on the
left side, symptoms have deteri-
orated recently. Bilateral knee
osteoarthritis is severe. On the
right side (a and b), this is
associated with remodeling of
the articular surfaces and sub-
chondral sclerosis. No edema or
cyst formation is present. On the
left, extensive bone marrow
lesion (c) is present with a focal
area of diminished signal seen
adjacent to the tibial plateau
(arrow in d). This presumably
represents a sclerotic response to
more focal stress/hyaline
cartilage damage
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ogy findings in OA suggest that BML seen on MRI reflects
metaplastic fibrovascular tissue in the bone marrow together
with trabecular remodeling. However, most BML fluctuate
in size over time, which may be observed after only a few
months suggesting that BML reflect more active histopath-
ological changes than structural remodeling [150–155]. In
one of these reports, fluctuations in BML scores over
3 months were positively correlated with changes in urinary
C-terminal crosslinking telopeptide of type II collagen, a
biomarker reflecting cartilage turnover [150].
A cross-sectional study of patients with knee OA found a
strong association between BML and pain [156]. Amongst
patients with pain, 77.5% showed BML on MRI, while
these lesions were detected in only 30% of patients without
pain. In 2007, the same working group reported the results
of a 15 month follow-up study [157]. An increase in BML
volume was observed in 49.1% of patients with painful
knee OA as opposed to only 26.8% of OA patients without
knee pain. Among patients with no BML at baseline, the
development of new BML was more common in painful
knees than in control knees (32.4 versus 10.8%). A recently
published self-matched case-control study in patients with
knee OA showed that changes in BML extent and synovitis
were associated with fluctuations in knee pain; improve-
ment of BML, but not of synovitis or effusion, was
associated with a decreased risk of knee pain [158].
Fig. 6 Unpredictability of presence and distribution of bone marrow
lesions in osteoarthritis. Right knee MRI in two patients (patient 1 a
and b; patient 2 c and d) with STIR and PD images. Two 60-year-old
women with right knee pain and instability with recent onset of
symptoms with near-normal weight-bearing radiographs 8 weeks
previously (preserved joint space with tiny osteophytes only). Both
patients had tears of the root attachment of the posterior horn of the
medial meniscus (not shown) and some medial extrusion of the body
of the meniscus. Cartilage loss is a little worse in the first patient, and
an extensive bone marrow lesion in the femoral condyle is associated
with a focal area of low signal in the subchondral bone without loss of
integrity of the articular contour (arrow in b). This likely represents
occult osteochondral injury without any substantial area of necrosis.
The second patient has an extensive bone marrow lesion in the tibial
plateau (c). Although the association of an overweight middle-aged
female with meniscal root or radial tear and rapid deterioration of
osteoarthritis is well established, the exact distribution of bone marrow
signal change, speed of progression, and the presence of co-existent
osteonecrosis are unpredictable
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However, a recent systematic literature review evaluating
the association between active and structural MR findings
and pain in patients with knee OA concluded that the level
of evidence for a positive association between either BML
or synovitis/effusion and pain is only moderate [159]. The
odds ratio for having pain when BML was present ranged
from 2.0 to 5.0 and for synovitis/effusion from 3.2 to 10.0.
In patients with radiographic knee OA, many studies
consistently showed an association of BML with cartilage
loss and OA progression [151, 154, 160–163], even in
patients with minimal baseline cartilage damage [164].
Absence of BML was associated with a decreased risk of
cartilage loss [154]. The risk for structural progression in
the medial and lateral compartment was increased more
than sixfold when medial or lateral BML were present
(adjusted odds ratio 6.5 with medial BME present and 6.1
with lateral BML present) [160]. Varus or valgus limb
malalignment is a confounder in the assessment of the
relationship between BML and structural progression [151,
160]. A recent report showed that meniscal pathology also
increases the risk of incident or enlarging BML over a
period of 30 months [165] and may not be an independent
predictor of structural progression.
A prospective cohort study in 271 healthy community-
based adults with no clinical knee OA showed incident
BML developing over the 2 year study period in 14%
[153]. Incident BML were associated with knee pain (odds
ratio 4.2) and with increased BMI. Of the BML present at
baseline, 46% completely resolved. In a prospective cohort
of 148 healthy women in middle age with no knee pain and
no clinical knee OA, large BML were associated with
progression of tibiofemoral cartilage defects [166]. These
data suggest that the relationship between BML and
cartilage loss is similar in knees with established OA and
in knees without clinical knee OA or pain.
Synovitis The optimal MRI evaluation of synovitis in knee
OA requires contrast enhancement. Synovial enhancement
by the contrast agent provides superior image quality for
the assessment of synovial volume and differentiates
synovitis from joint effusion by increased vascular perfu-
sion and capillary permeability of the synovium [167].
Synovitis scores obtained by contrast-enhanced MRI
showed good correlation with arthroscopic and microscopic
synovitis scores [168]. Studies using nonenhanced MRI
showed inconsistent results regarding an association be-
tween synovitis and knee pain. A recent report showed that
synovitis detected by contrast-enhanced MRI had a strong
association (adjusted odds ratio 9.2) with at least moderate
severity of knee pain as assessed by the Western Ontario
and McMaster Osteoarthritis Index pain scale [169]. A
comprehensive whole-knee joint synovitis scoring system
has been proposed recently, which showed a high reliability
based on contrast-enhanced MRI [170]. Interventional
studies assessing intraarticular corticosteroids or NSAIDs
and paracetamol demonstrated associations between de-
creased synovitis and reduction of pain in patients with
knee OA [171, 172]. Several semiquantitative and quanti-
tative contrast-enhanced MRI assessment systems using
different subregional approaches have been proposed to
quantify synovitis [65, 167, 173–175].
Future directions
Future research in axial SpA should focus on further
prospective assessment of the utility of structural lesions
in more diverse settings and larger cohorts of patients
suspected of having early SpA. It is also important for
clinicians to know to what degree imaging of the spine
contributes to diagnostic utility over and above assessment
of the SIJ, which might in turn argue in favor of the use of
WB MRI over conventional imaging. Finally, it is impor-
tant to understand the prognostic significance of lesions
observed on MRI and to what degree and which features
portend an unfavorable radiographic outcome.
In addition to the documented utility for risk stratifica-
tion for erosive progression in early RA and for early
diagnosis of RA, other areas where MRI may be clinically
important are emerging. Important research areas include
whether adding MRI to routine clinical examination will
improve clinical and radiographic outcome in RA patients.
In particular, it is important to understand the prognostic
significance of MRI findings in those patients achieving
clinical remission with respect to the subsequent course of
erosive progression, functional impairment, and disease
activity. Technical advances, including the possibility of
achieving overall assessment of the disease load by WB
MRI and the potential clinical and scientific utility of
improved cartilage assessment, e.g., by 3 T MRI, should be
evaluated.
Research in OA should evaluate treatment interventions
targeting BML and synovitis. These MRI signs of disease
activity are potentially reversible, and there is some
evidence that their improvement may also preserve joint
integrity. Before using MRI for OA in daily routine, we
need data that address whether a diagnosis of preradio-
graphic OA by MR, which may facilitate early intervention,
translates into a more favorable clinical outcome.
MRI is a very promising imaging modality not only for
our understanding of the pathophysiology of axial SpA,
RA, and OA and for confirming an early diagnosis before
radiographic lesions appear, but also for monitoring disease
upon treatment due to its noninvasive technique, lack of
ionizing radiation, and its superior spatial and contrast
resolution of all tissues involved in the disease process.
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